Beyond Oil Ltd. has officially opened the market on December 8, 2025, celebrating its new listing on the Toronto Stock Exchange (TSX: BOIL). The event took...
Incyte Corporation announced on October 29, 2023, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug, INCA033989. This...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Incyte’s experimental drug, INCA033989, aimed at treating a rare blood cancer known as...
The U.S. Food and Drug Administration (FDA) has officially extended the review period for the New Drug Application (NDA) concerning Ascendis Pharma’s treatment for children with...
The U.S. Food and Drug Administration (FDA) has initiated a trial program aimed at improving communication with pharmaceutical companies regarding pending drug applications. Launched in October...
The U.S. Food and Drug Administration (FDA) has announced a significant recall of more than 580,000 bottles of the blood pressure medication prazosin hydrochloride. This action...
The U.S. Food and Drug Administration (FDA) has announced a significant recall affecting over 580,000 bottles of the blood pressure medication prazosin hydrochloride. The recall, initiated...
Akebia Therapeutics has announced it will discontinue its efforts to expand the use of Vafseo (vadadustat) for treating anemia in patients with chronic kidney disease (CKD)...
The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Elanco Animal Health for its product Credelio (active ingredient: lotilaner). This authorization...
atai Life Sciences and Beckley Psytech have been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for their investigational nasal spray, BPL-003,...
